Beximco Pharmaceuticals Limited
Stock Forecast, Prediction & Price Target

	Passed			Analyst forecast
Metric	6/30/2021	6/30/2022	6/30/2024	6/30/2026	6/30/2027	6/30/2028
Revenue % change YoY	£29.49B N/A	£34.66B 17.54%	£44.39B 28.04%	Avg: £58.74B Low: £58.74B High: £58.74B avg. 32.34%	Avg: £70.43B Low: £70.43B High: £70.43B avg. 19.89%	Avg: £80.11B Low: £80.11B High: £80.11B avg. 13.73%
Net Income % change YoY	£5.12B N/A	£5.12B -0.08%	£5.82B 13.78%	Avg: £7.06B Low: £7.06B High: £7.06B avg. 21.22%	Avg: £8.63B Low: £8.63B High: £8.63B avg. 22.16%	Avg: £9.85B Low: £9.85B High: £9.85B avg. 14.20%
EBITDA % change YoY	£7.38B N/A	£7.68B 4.07%	£8.68B 12.95%	Avg: £12.85B Low: £12.85B High: £12.85B avg. 47.97%	Avg: £15.40B Low: £15.40B High: £15.40B avg. 19.89%	Avg: £17.52B Low: £17.52B High: £17.52B avg. 13.73%
EPS % change YoY	$11.49 N/A	$11.48 -0.08%	$13.07 13.85%	Avg: $15.84 Low: $15.84 High: $15.84 avg. 21.16%	Avg: $19.35 Low: $19.35 High: $19.35 avg. 22.16%	Avg: $22.09 Low: $22.09 High: $22.09 avg. 14.20%
Operating Expenses % change YoY	£7.59B N/A	£9.27B 22.07%	£10.95B 18.19%	Avg: £14.68B Low: £14.68B High: £14.68B avg. 33.99%	Avg: £17.60B Low: £17.60B High: £17.60B avg. 19.89%	Avg: £20.02B Low: £20.02B High: £20.02B avg. 13.73%

FAQ

Wall Street analysts estimate the annual average earnings growth rate of 19.19% in 2026-2028.

We have gathered data from N/A analysts. Their low estimate is 7.06B, average is 7.06B and high is 7.06B.

Wall Street analysts forecast annual average revenue growth of 21.99% in 2026-2028.

We have gathered data from N/A analysts. Their low revenue estimate is £58.74B, average is £58.74B and high is £58.74B.

Wall Street analysts forecast annual average earnings growth of 19.17% in 2026-2028.

We have gathered data from N/A analysts. Their low earnings per share estimate is $15.84, average is $15.84 and high is £15.83.